Radius Health Inc (NASDAQ:RDUS) shares rose 6.7% during trading on Thursday . The company traded as high as $36.93 and last traded at $36.12. Approximately 1,310,321 shares changed hands during trading, an increase of 35% from the average daily volume of 967,825 shares. The stock had previously closed at $33.86.

RDUS has been the subject of a number of recent research reports. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. BidaskClub upgraded Radius Health from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Goldman Sachs Group restated a “neutral” rating and set a $45.00 price objective on shares of Radius Health in a research note on Friday, October 6th. Maxim Group restated a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Finally, Jefferies Group lowered their price objective on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $48.00.

The stock has a market cap of $1,780.00, a P/E ratio of -7.00 and a beta of 1.10. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period last year, the firm posted ($1.07) earnings per share. sell-side analysts predict that Radius Health Inc will post -5.57 EPS for the current year.

In other news, VP Brent Hatzis-Schoch acquired 1,778 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was acquired at an average price of $28.09 per share, for a total transaction of $49,944.02. Following the completion of the acquisition, the vice president now directly owns 2,278 shares in the company, valued at approximately $63,989.02. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was purchased at an average price of $26.25 per share, with a total value of $1,312,500.00. Following the acquisition, the insider now owns 5,698,799 shares of the company’s stock, valued at $149,593,473.75. The disclosure for this purchase can be found here. In the last three months, insiders bought 158,578 shares of company stock valued at $4,659,916. Company insiders own 15.00% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Radius Health in the third quarter valued at $110,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 541 shares during the period. Advisor Group Inc. lifted its holdings in shares of Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 2,888 shares during the period. Amalgamated Bank acquired a new stake in shares of Radius Health in the second quarter valued at $211,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of Radius Health by 14.1% in the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock valued at $308,000 after buying an additional 839 shares during the period.

ILLEGAL ACTIVITY WARNING: “Radius Health (RDUS) Stock Price Up 6.7%” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/01/20/radius-health-rdus-stock-price-up-6-7.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.